Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Inc (PVLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,330,011
  • Shares Outstanding, K 11,836
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,430 K
  • EBIT $ -29 M
  • EBITDA $ -27 M
  • 60-Month Beta -0.30
  • Price/Sales -26,600.22
  • Price/Cash Flow N/A
  • Price/Book 33.63

Options Overview Details

View History
  • Implied Volatility 80.44% (-4.15%)
  • Historical Volatility 116.45%
  • IV Percentile 49%
  • IV Rank 7.65%
  • IV High 246.56% on 02/17/26
  • IV Low 66.67% on 12/18/25
  • Expected Move (DTE 19) 16.11 (14.33%)
  • Put/Call Vol Ratio 2.50
  • Today's Volume 42
  • Volume Avg (30-Day) 277
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 5,219
  • Open Int (30-Day) 5,326
  • Expected Range 96.26 to 128.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.95
  • Number of Estimates 6
  • High Estimate -0.87
  • Low Estimate -1.03
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
109.36 +2.76%
on 03/20/26
143.76 -21.83%
on 03/10/26
-22.65 (-16.78%)
since 02/27/26
3-Month
72.22 +55.58%
on 01/30/26
151.18 -25.67%
on 02/26/26
+9.00 (+8.71%)
since 12/26/25
52-Week
18.23 +516.57%
on 04/09/25
151.18 -25.67%
on 02/26/26
+84.61 (+304.79%)
since 03/27/25

Most Recent Stories

More News
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization,...

PVLA : 112.37 (-4.46%)
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026

WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc.  (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and...

PVLA : 112.37 (-4.46%)
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its...

KRYS : 245.39 (-2.39%)
PVLA : 112.37 (-4.46%)
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular...

PVLA : 112.37 (-4.46%)
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers , and healthcare professionals Campaign developed and launched in close collaboration with leading nonprofit...

PVLA : 112.37 (-4.46%)
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...

PVLA : 112.37 (-4.46%)
Palvella Therapeutics Announces Pricing of Upsized Public Offering

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies...

PVLA : 112.37 (-4.46%)
Stocks Settle Higher as AI Disruption Fears Ease

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.77%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.76%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.09%. March E-mini...

AMAT : 337.17 (-0.41%)
HSIC : 72.10 (-2.18%)
DDOG : 114.48 (-7.90%)
EXPD : 141.22 (-1.01%)
TRI : 89.43 (-1.05%)
$IUXX : 23,132.77 (-1.93%)
BWXT : 202.59 (-1.22%)
ASML : 1,302.47 (-2.03%)
ZNM26 : 110-150 (+0.28%)
ESM26 : 6,405.00 (-0.11%)
QCOM : 127.11 (-2.63%)
KEYS : 279.06 (-0.72%)
Palvella Therapeutics Announces Proposed Public Offering

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies...

PVLA : 112.37 (-4.46%)
Stocks Rally as AI-Fueled Worries Ease

The S&P 500 Index ($SPX ) (SPY ) today is up +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.90%. March E-mini S&P futures (ESH26...

INTU : 416.44 (-3.72%)
HSIC : 72.10 (-2.18%)
ADI : 307.44 (-1.91%)
EXPD : 141.22 (-1.01%)
TRI : 89.43 (-1.05%)
TXN : 190.33 (-1.59%)
$IUXX : 23,132.77 (-1.93%)
BWXT : 202.59 (-1.22%)
ZNM26 : 110-150 (+0.28%)
ESM26 : 6,405.00 (-0.11%)
FANG : 201.84 (-0.17%)
QCOM : 127.11 (-2.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

See More

Key Turning Points

3rd Resistance Point 124.82
2nd Resistance Point 122.09
1st Resistance Point 117.23
Last Price 112.37
1st Support Level 109.63
2nd Support Level 106.90
3rd Support Level 102.04

See More

52-Week High 151.18
Last Price 112.37
Fibonacci 61.8% 100.39
Fibonacci 50% 84.70
Fibonacci 38.2% 69.01
52-Week Low 18.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.